- Conditions
- Obesity
- Interventions
- Phentermine-Topiramate, Meal Replacement Therapy, Placebo
- Drug · Dietary Supplement · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 941
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- Interventions
- ANG003 Dose A, ANG003 Dose B, Creon
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 27
- States / cities
- Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- Gout
- Interventions
- Bucillamine, Colchicine
- Drug
- Lead sponsor
- Revive Therapeutics, Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- San Roman, California • Arlington, Texas • San Antonio, Texas
- Conditions
- Hemophilia A
- Interventions
- rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222)
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years to 70 Years · Male only
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 20
- States / cities
- Orange, California • Sacramento, California • San Francisco, California + 17 more
- Conditions
- Ulcerative Colitis
- Interventions
- SHR0302, Placebo
- Drug
- Lead sponsor
- Reistone Biopharma Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 23
- States / cities
- Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more
- Conditions
- Huntington Disease
- Interventions
- SKY-0515, SKY-0515 Placebo
- Drug
- Lead sponsor
- Skyhawk Therapeutics, Inc.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Englewood, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
- Conditions
- Malaria, Lymphatic Filariasis
- Interventions
- Ivermectin, Albendazole
- Drug
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- Not listed
- Enrollment
- 2,712 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Encinitas, California • Encino, California + 41 more
- Conditions
- Healthy
- Interventions
- meropenem-vaborbactam, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Psychedelic Effects in Healthy Volunteers
- Interventions
- Pindolol, Placebo, Psilocybin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
- Interventions
- Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
- Device · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Contraception
- Interventions
- Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 346 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more
- Conditions
- Glioma
- Interventions
- Lenvatinib, Bevacizumab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Boston, Massachusetts • Durham, North Carolina
- Conditions
- Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
- Interventions
- Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
- Drug · Device
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Health Behavior, Health Care Utilization
- Interventions
- Phase II Promotores de Salud, Phase I Promotores de Salud Outreach
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Narcolepsy Type 1 (NT1)
- Interventions
- E2086, E2086 Placebo, Active Comparator, Active Comparator Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 12
- States / cities
- Santa Ana, California • Miami, Florida • Macon, Georgia + 9 more
- Conditions
- Acne Vulgaris
- Interventions
- FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
- Combination Product · Drug · Other
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 35
- States / cities
- Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
- Conditions
- Healthy
- Interventions
- Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Duarte, California • Glendale, California + 33 more
- Conditions
- Dementia, Alzheimer Disease, Relationship, Marital, Caregiver Stress Syndrome
- Interventions
- READyR A, READyR B
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 62 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Gout
- Interventions
- Arhalofenate, Allopurinol, Colchicine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 16
- States / cities
- Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Spinal Cord Injuries
- Interventions
- Heated Vest, Non-Heated Vest
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
- Interventions
- Lenvatinib, ABBV-324
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 10
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 7 more